Sanofi (SAN FP) and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
Importance
Level 1
#FRANCE#EUROPE#SANOFI#SAN.FP#BANCO SANTANDER SA#EQUITIES#EU SESSION#PHARMACEUTICALS#DIVERSIFIED BANKS#PHARMACEUTICALS (GROUP)#BANKS#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#BANKS (GROUP)#SAN#EURO STOXX 50#CAC 40 INDEX#SANOFI SA#CAC#GLOBAL NEWS